Clinical Trials Logo

Clinical Trial Summary

This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with high morbidity and mortality. The fulminant course of NSTIs demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presentation, in co-morbidities and in microbiological aetiology. Thus, there is an urgent need for novel diagnostics and therapeutics in order to improve outcome of NSTIs. A comprehensive knowledge of diagnostic features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host and bacterial disease traits and their underlying interaction network) is required for an improved diagnosis and management of NSTIs. The current proposal is designed to obtain such insights through an integrated systems biology approach in patients and experimental models. The project is based on a prospective NSTI patients cohort including a clinical registry to document clinical data and treatment strategies, combined with an isolate and biobank collection. The samples will be analyzed through advanced bioinformatics and computational modelling work flow to identify and quantify pathogen signatures and underlying networks that contribute to disease outcome. One aim is to translate clinical and systems biology data into development of novel diagnostics.


Clinical Trial Description

Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska University Hospital, Blekinge University, Sahlgrenska University and University of Bergen). Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging and laboratory tests have little predictive value in the early stage. The gold standard modality for diagnosis of NSTI remains operative exploration. Operative findings that are consistent with NSTI include "dishwater or foul smelling discharge, necrosis or lack of bleeding and loss of the normal resistance of the fascia to finger dissection. A patient admitted for critical care and / or surgery due to severe soft tissue infection of the fascia, muscle or subcutaneous tissues will be enrolled in this NSTI study. The patients will be stratified based on several clinical parameters including among others SAPS score, presence of multiorgan failure, and hypotensive shock. This stratification serves to classify the patients in defined severity classes to be used in analyses and modeling. Detailed demographic and clinical information will be documented in the interactive database including: age, gender, medical history, clinical presentation (shock, multiorgan failure etc), treatment and outcome. Disease progress: The clinical database is to contain information on the spread of the infection at the different times of inspection/surgical intervention. Severity of the infections will be documented by use of the updated CREST classification scheme, SAPS III score, and the LRINEC score. Detailed information regarding antimicrobial therapy, surgical intervention, innovative therapy (IVIG and HBO) will be documented.

Samples will be collected from all enrolled patients. Standard operating procedures will be generated and implemented at all sites to ensure a quality assured collection and handling of samples. Samples to be collected include (a) isolates, (b) blood samples to be processed for DNA, RNA and plasma/cells and (c) tissue biopsies in all patients whenever surgical interventions are indicated. The samples will be analyzed using genomics, transcriptomics, metabolomics and proteomics. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01790698
Study type Observational [Patient Registry]
Source Karolinska Institutet
Contact
Status Completed
Phase
Start date January 2013
Completion date January 2018

See also
  Status Clinical Trial Phase
Completed NCT04332679 - Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes N/A
Completed NCT00187759 - Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection N/A
Completed NCT02097615 - Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water Phase 4
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Active, not recruiting NCT04257097 - Reinforced PTFE Meshes Versus Customized Titanium Meshes N/A
Enrolling by invitation NCT05826873 - Discharge Stewardship in Children's Hospitals N/A
Completed NCT04393909 - Improving Safety of Diagnosis and Therapy in the Inpatient Setting N/A
Active, not recruiting NCT02595047 - Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint) N/A
Completed NCT00785200 - MRSA Colonization and Control in the Dallas County Jail N/A
Completed NCT00426933 - Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections Phase 2
Terminated NCT00102947 - Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections Phase 4
Completed NCT00451386 - Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) Phase 2
Completed NCT03643952 - Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Phase 2
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Completed NCT02600871 - Skin and Soft Tissue Infection (SSTI) Study Phase 4
Completed NCT00303589 - A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections Phase 2
Completed NCT04286334 - Three-dimensional Bone Regeneration Using Custom-made Meshes With and Without Collagen Membrane N/A
Recruiting NCT05471908 - Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial N/A
Withdrawn NCT03982030 - Dalbavancin Outpatient Pilot Phase 4
Terminated NCT00430937 - Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections Phase 3